Related by context. All words. (Click for frequent words.) 70 ENDEAVOR IV 69 Carotid Revascularization Endarterectomy vs. 69 multicenter prospective 69 prospective multicenter 69 prospective randomized multicenter 69 Stenting Trial CREST 68 multicenter Phase II 68 multicenter randomized clinical 68 prospective nonrandomized 68 randomized Phase IIb 68 multicentre randomized controlled 67 CARE HF 67 EchoCRT 67 phase IIIb 67 prospective multicentre 67 double blinded randomized 67 multicenter randomized controlled 67 ONTARGET 67 Prospective Randomized 67 prospective randomized controlled 67 multicentre randomized 67 randomized multicenter 67 randomized controlled multicenter 66 landmark ATHENA 66 Phase III multicenter 66 PRoFESS 66 RE LY ® 66 multicenter randomized 66 multicenter clinical 66 Randomized Evaluation 66 Multicenter 66 multicentre 66 ACRIN 66 RE LY 65 Val HeFT 65 multicenter multinational 65 NICE SUGAR 65 PARTNER Trial 65 ExTRACT TIMI 65 TG MV 65 CALGB # [002] 65 HORIZONS AMI 65 multicenter randomized placebo controlled 65 Randomized controlled 65 placebo controlled Phase III 64 Group RTOG 64 CHAMPION PCI 64 Digital Mammographic Imaging 64 blinded randomized controlled 64 Pivotal Trial 64 TAXUS ATLAS 64 Delcath Phase III 64 prospective randomized 64 AFRS TM 64 MADIT II 64 EVEREST II 64 placebo controlled clinical 64 randomized Phase III 64 STENT 64 ENESTnd 64 ECASS 64 REACH Registry 64 prospective multicenter randomized 64 nonrandomized 63 multicentre prospective 63 PFO migraine 63 CALGB 63 CLARITY TIMI 63 Prospective Multicenter 63 multicenter phase 63 Phase III VISTA 63 LUMINATE 63 ADVANCE PD 63 RE MODEL 63 Intervention Effectiveness 63 Phase 2b kidney transplant 63 ENDEAVOR III 63 prospective multicenter study 63 prospective randomized placebo 63 randomized multicenter trial 63 Phase IIIb study 63 Edge STudy 63 Intervention Trial GAIT 63 Phase Ib IIa 63 randomized controlled clinical 63 WallFlex Biliary RX 63 prospective observational 63 PERSEUS 63 ACUITY trial 63 NCT# ClinicalTrials.gov 63 Spine Patient Outcomes 63 Aggressive Reduction 63 Phase IIIb clinical 63 BARI 2D 63 ILLUSTRATE 62 Embolic Protection Device 62 Pivotal Clinical Trial 62 Phase IIb III 62 Screening Trial DMIST 62 PRESEPT 62 TRITON TIMI 62 controlled multicenter 62 retrospective observational study 62 NATRECOR ® 62 Aneurysm Repair 62 SPIRIT IV 62 retrospective cohort study 62 AVERROES 62 BRIM2 62 PROactive study 62 BCIRG 62 Prospective Randomized Trial 62 observational cohort study 62 multicenter randomized double 62 multicenter 62 Acute Coronary Syndromes 62 Acute Myocardial Infarction 62 Phase IIIb 62 blinded randomized placebo controlled 62 PROTECT AF 62 Acute Decompensated Heart Failure 62 ARBITER 6 62 Phase III randomized 62 ASCEND HF 62 EDEMA3 62 ASTEROID 62 CYPHER ® Sirolimus eluting 62 multicentre study 62 PREVENT IV 62 Phase Ib clinical 62 PRECISE 62 Sirolimus eluting 62 confirmatory clinical 61 randomized controlled 61 BioNumerik 61 AIM HIGH 61 blind multicenter 61 pharmacokinetic PK study 61 comparing XIENCE V 61 Refractory Angina 61 EURIDIS 61 unfractionated heparin UFH 61 multicenter placebo controlled 61 SPIRIT FIRST 61 TAXUS VI 61 carotid artery stenting CAS 61 Surgical Treatment 61 multicenter Phase 61 DAPT Study 61 multicentre randomized double 61 ROCKET AF 61 recurrent glioblastoma multiforme 61 ToGA 61 thorough QT 61 Carotid Stenting 61 MERLIN TIMI 61 Urology Gynecology 61 Patient Outcomes 61 MEND CABG 61 Paclitaxel eluting 61 phase IIb clinical 61 phase IIa 61 MADIT CRT 61 phase IIa clinical 61 SCD HeFT 61 Randomized Clinical Trial 61 Heart Failure Trial 61 Radiation Therapy Oncology 61 HYVET 61 RIO Lipids 61 blinded randomized 61 MYTHOS trial 61 Myocardial Infarction Study 61 Decompensated Heart Failure 61 HORIZONS AMI trial 61 NSABP B 61 TAXUS Express2 61 Multicenter Automatic Defibrillator Implantation 61 Medidur TM FA 61 CLARITY study 61 randomized blinded 61 double blinded placebo 61 NeuroFlo 61 AVOREN 61 TIMI Study Group 61 IMPACT DCM 61 Eluting Stent 61 everolimus eluting stent 61 Raloxifene Evaluation MORE 60 label multicenter 60 prospectively randomized 60 STRIDE PD 60 subanalysis 60 AA Amyloidosis 60 Aflibercept 60 Patency 60 Dual Antiplatelet Therapy 60 XIENCE V Stent System 60 recurrent malignant glioma 60 NEVO 60 treatment naive genotype 60 phase IIb study 60 CHARM Added 60 RhuDex 60 Xelox 60 Phase Ib IIa clinical 60 Intervention Effectiveness CATIE 60 Placebo controlled 60 MIVI III 60 dose escalation clinical 60 CIMZIA TM certolizumab pegol 60 Phase Ib II 60 antiretroviral naïve 60 TAXUS IV 60 ENGAGE AF TIMI 60 MADIT 60 CHARISMA trial 60 Cholesterol Levels SPARCL 60 longitudinal cohort study 60 Sipuleucel T 60 RE LY trial 60 Multicentre 60 Acute Ischemic Stroke 60 multicenter study 60 Nesiritide 60 carotid artery stenting 60 Renal Cell Carcinoma RCC 60 Medtronic CoreValve 60 Endeavor Drug Eluting 60 NATRECOR R 60 fosbretabulin 60 substudy 60 CaPSURE 60 VADT 60 ABSORB trial 60 clevidipine 60 APEX PD 60 Randomized Study 60 evaluating tivozanib 60 Platelet Inhibition 60 ACCOMPLISH 60 Phase #b/#a clinical 60 phase Ib 60 Clinical Evaluation 60 Angiographic 60 Phase IIIB IV 60 Phase #/#a 60 REMEDIAL II 60 Phase III AFFIRM 60 TRA 2P 60 masked placebo controlled 60 Heterozygous Familial Hypercholesterolemia 60 Initiated Phase 60 Cellular Therapies 60 pain palliation 60 Spectranetics laser 60 Percutaneous Coronary Intervention 60 Left Ventricular Dysfunction 60 Echocardiographic 60 Endovascular Valve Edge 59 BrachySil ™ 59 Hepatocellular Carcinoma HCC 59 BR.# 59 DIRECT Trial 59 Evaluation WISE 59 randomized clinical 59 Phase III psoriasis 59 Endeavor drug eluting 59 Bare Metal Stent 59 ACCORD Lipid 59 ALN VSP Phase 59 Thrombolysis 59 VESTASYNC 59 BRIM3 59 ADHERE 59 abacavir Ziagen 59 NAVISTAR R 59 Vascugel 59 Gynecologic Oncology Group 59 MAGE A3 ASCI 59 ADMIRE HF 59 EINSTEIN DVT 59 Prostate Lung Colorectal 59 number NCT# ClinicalTrials.gov 59 RESOLUTE clinical 59 GOUT 59 Trandolapril 59 multicentric 59 catheter occlusion 59 Neuradiab TM 59 HCV SPRINT 59 Fondaparinux 59 atherosclerotic renal artery stenosis 59 Randomised 59 Patrick Serruys 59 SilverHawk Plaque Excision System 59 Phase #b/#a 59 multicenter Phase III 59 Deutsches Herzzentrum 59 SYNTAX trial 59 Lipid Lowering Treatment 59 HeartNet 59 retrospective cohort 59 Surgical Mesh 59 Phase III Pivotal 59 longitudinal observational study 59 Clinical Antipsychotic Trials 59 Diastolic Heart Failure 59 randomized crossover 59 recurrent glioma 59 MIST II 59 viral kinetic 59 Phase III Psoriasis 59 relapsed MM 59 modified REGENESIS Phase IIb 59 CYPHER Stent 59 HCV RESPOND 2 59 AIR CF1 59 Demonstrates Sustained 59 neratinib 59 SWOG 59 non valvular atrial 59 Zemplar Capsules 59 Renal Artery 59 Eluting Coronary Stent System 59 midstage clinical 59 gefitinib Iressa 59 undergoing elective percutaneous 59 Screening Trial 59 multicenter trials 59 Transcatheter 59 Peripheral Arterial 59 phase IIb 59 Therapeutics TCT scientific 59 AIR CF3 59 Phase 1b trial 59 HF ACTION 59 CAPRIE 59 PROMUS R 59 Randomized Double blind 59 Unstable Angina 59 DES implantation 59 IL# PE#QQR 59 NSABP 59 Randomized Controlled 59 Onrigin 59 Phase III metastatic melanoma 59 GISSI HF 59 everolimus eluting 59 pegylated interferon alfa 2b 59 mg/m2 cohort 59 HeFT 59 EXPLORE Xa 59 Amorcyte 59 everolimus eluting stents 59 Multicenter Study 59 EmbraceAC 59 registrational Phase 59 Dr. Kandzari 59 randomized multicentre 59 RSD# oral 59 retrospectively analyzed 59 PROTEGE 59 Embolic Protection 58 REVIVE Diabetes 58 RE COVER 58 Zenvia Phase III 58 FIX HF 5 58 Percutaneous Tibial Nerve Stimulation 58 pharmacokinetic PK 58 PhotoPoint R 58 Daclizumab 58 brivaracetam 58 Phase 1a clinical 58 Zarnestra 58 ALSYMPCA 58 placebo controlled randomized 58 Vascugel ® 58 CYPHER R Sirolimus eluting 58 Dose Ranging Study 58 AVADO 58 GORE TAG Device 58 Teriflunomide 58 CURRENT OASIS 7 58 riociguat 58 patients undergoing percutaneous 58 Chronic Heart Failure 58 carotid endarterectomy CEA 58 ORAL Sync 58 Pemetrexed 58 RECORD1 58 Rheos System 58 blinded placebo controlled 58 PRIMO CABG 58 acadesine 58 Long Term Efficacy 58 PERSEUS clinical program 58 multicenter randomized Phase III 58 basal bolus regimen 58 Vertos II 58 dose escalation Phase 58 Endoscopic Ablation System 58 prospective observational cohort 58 trial evaluating PRX# 58 phase IIb III 58 sorafenib Nexavar 58 Coronary Revascularization 58 Carotid Endarterectomy 58 dose escalation phase 58 TMC# C# 58 biliary tract cancer 58 phase IIb trial 58 zotarolimus eluting stent 58 UEGW 58 COPERNICUS 58 observational cohort 58 portal vein thrombosis 58 Sibutramine Cardiovascular Outcomes 58 ZACTIMA 58 VEITHsymposium 58 Prostate Cancer Prevention 58 Cardiac Resynchronization Therapy 58 Combination REOLYSIN R 58 assessing T DM1 58 placebo controlled Phase 58 ANCHOR trial 58 ARIXTRA 58 PROMUS TM 58 unstable angina UA 58 RezularTM 58 carotid artery stent 58 prospective longitudinal 58 Study Evaluating 58 ICON7 58 SUCCEED trial 58 Proellex TM 58 CONQUER OB 58 underwent CABG 58 NEVO RES 58 Current Controlled Trials 58 Catheter Ablation 58 NCCTG N# 58 KRN# 58 evaluating Actimmune 58 Acute myocardial infarction 58 randomized discontinuation 58 TAXUS TM 58 Stereotactic Body Radiation Therapy 58 liposome injection 58 somatostatin analog 58 rt PA 58 COSTAR II 58 DU #b 58 drug eluting coronary stents 58 CATIE AD 58 ASBMR 58 active comparator 58 acute PAO 58 rALLy clinical trial 58 Dr. Nabil Dib 58 TLK# 58 XIENCE V Everolimus Eluting 58 SPARCL 58 EORTC 58 oral ridaforolimus 58 HealthCore 58 blind randomized placebo 58 Cardiac Allograft Rejection 58 urethral bulking agent 58 ONTARGET R 58 papillary renal cell carcinoma 58 GEM OS1 58 BEZ# 58 paclitaxel eluting 58 CUSTOM III 57 placebo controlled multicenter 57 cisplatin vinorelbine 57 Uterine Cancer 57 Temsirolimus 57 evaluating REVLIMID 57 recurrent metastatic 57 Adjunctive 57 VATS lobectomy 57 oral deforolimus 57 NCIC CTG 57 See CLINICAL PHARMACOLOGY 57 ANN INTERN MED 57 Carotid 57 NO# [002] 57 ENDEAVOR II 57 Severe Sepsis 57 OLYMPIA registry 57 CINQUIL 57 Myelodysplastic Syndrome MDS 57 COSIRA trial 57 budesonide foam 57 Phase III Clinical Trial 57 II Clinical Trial 57 PreCISe 57 Phase 2b Clinical Trial 57 Diabetes ACCORD 57 PFO closure 57 CAMMS# 57 DEEP AF 57 LHRH receptor positive 57 LibiGel Phase III 57 Phase 1b clinical trials 57 Enzastaurin 57 Coronary Angiography 57 pivotal bioequivalence 57 PICSO ® 57 Scandinavian Cardiac Outcomes 57 Oncologic 57 AIR2 Trial 57 retinal vein occlusion induced 57 Stenting 57 Pivotal Phase III 57 RAVEL 57 Ophena TM 57 randomized blinded placebo 57 Angiox R 57 TASKi3 57 Acute Myocardial Infarction AMI 57 solithromycin 57 Coherex FlatStent 57 phase III isavuconazole 57 CALERIE 57 Rosuvastatin 57 RELOVAIR ™ 57 Phase #b/#a trial 57 STICH trial 57 Phase 1b clinical 57 stent DES 57 ELCAP 57 OPTIMIZE HF 57 Abciximab 57 IIa clinical 57 noninvasive outpatient 57 Trial ASCOT 57 SUTENT ® 57 Multicenter Phase 57 INSPIRE Trial Phase III 57 MelaFind pivotal 57 Randomized Controlled Trials 57 placebo controlled dose escalation 57 Outpatient Setting 57 coronary stent merged 57 Clinical Outcomes Utilizing Revascularization 57 Urocortin 2 57 NCCTG 57 coronary intervention 57 PROTECT II 57 noninferior 57 Phase IIA 57 GSK# [001] 57 ACTIVE W 57 QUASAR validation study 57 AVN# Phase 57 SIMPADICO 57 Subgroup analysis 57 ADAGIO study 57 clinical trial 57 laparoscopic fundoplication 57 RESOLUTE 57 Orqis Medical 57 Phase 2b Study 57 venous thromboembolic disease 57 SORT OUT III 57 Intravitreal 57 ASCO GI 57 eluting stent 57 Anticoagulation 57 Antihypertensive 57 Coronary Artery Bypass Grafting 57 AIR CF2 57 conducted retrospective cohort 57 HPTN 57 SNT-MC#/idebenone 57 R lenalidomide 57 Stent Thrombosis 57 ARIXTRA R 57 Randomized Placebo Controlled 57 Immunotherapeutic 57 Adenoma Prevention 57 Dr. Eberhard Grube 57 Gliadel Wafer 57 TM Everolimus Eluting 57 ECTRIMS 57 Cardiovascular Outcomes 57 ximelagatran 57 Dacogen decitabine 57 SABCS 57 Degarelix 57 Alpha Tocopherol Beta Carotene 57 Multicenter Randomized Double 57 patientswith 57 JenaValve 57 SYNTAX 57 Advanced Heart Failure 57 ug dose 57 Patient Registry 57 Deforolimus 57 Acute MI 57 Phase III ThermoDox 57 Dialysis Outcomes 57 CUSTOM II 57 National Emphysema Treatment 57 comparator arm 57 VICTOR E1 57 cobiprostone 57 Reduce Cardiovascular 57 VEITHsymposium TM 57 #I TM# 57 Long Lesion 57 Asthma Intervention 57 Pre RELAX AHF 57 Cloretazine R 57 thrombus aspiration 57 CRESTOR #mg 57 sirolimus eluting 57 acute coronary syndromes ACS 57 MEVACOR 57 TM Drug Eluting 57 PEARL SC 57 ILLUMINATE 57 Randomized Phase II 57 ASSERT 57 florbetaben 57 Antiplatelet 57 Phase III Trial 57 Clolar ® 57 mid urethral sling 57 Drug Eluting Stents 57 Randomized Clinical Trials 57 Randomized Phase 57 clinical pharmacology studies 57 Alfimeprase 56 sacral nerve stimulation 56 ABCSG 56 BZA CE 56 LUX Lung 56 treatment naïve genotype 56 Catheterization 56 azilsartan medoxomil 56 Pivotal Study 56 Observational Study 56 CRLX# 56 phase Ib clinical 56 OZURDEX ® 56 Clinical Trial Data 56 Ischemic Stroke 56 cardio renal 56 Truvada tablets 56 By JENNIFER LEARN 56 Myocardial Ischemia 56 Eluting 56 computed tomographic 56 Cypher Sirolimus 56 Eculizumab 56 mg administered orally 56 Cloretazine 56 MGd 56 Neuronetics 56 noninferiority 56 recurrent GBM 56 visceral metastases 56 PRECiSE 56 morphometric vertebral fractures 56 paclitaxel eluting stents 56 sitaxsentan 56 PLCO 56 RTOG 56 Augment Injectable 56 ZOLINZA 56 Ovarian Cancer Screening 56 APEX AMI 56 Intervention Trial 56 J Am Coll 56 Phase Ib study 56 carotid stents 56 Initiates Enrollment 56 DAPT 56 metastatic colorectal 56 acute myocardial infarction MI 56 Dabigatran 56 osteoporotic compression fractures 56 Coronary Artery Bypass Graft 56 dose dose escalation 56 EMPHASIS HF trial 56 randomized placebo controlled 56 kidney urologic 56 Liberte TM 56 Phase III placebo controlled 56 Polyp Prevention Trial 56 Nitinol Stent 56 Coronary Stent 56 SPIRIT III 56 Nebulized 56 MEND CABG II 56 liver resection 56 Serious Adverse Events 56 intravesical infusion therapy 56 ACCULINK 56 Aggressive Drug Evaluation 56 Xerecept 56 FASLODEX 56 PCI ExTRACT TIMI 56 Motesanib 56 Stenting Trial 56 rFVIIa 56 Controlled Trial 56 metastatic malignant 56 Traficet EN 56 Cardiovascular Interventions 56 chronic myocardial ischemia 56 Angiox ® 56 Phase IIB 56 DDP# 56 LEUKINE 56 Feasibility Trial 56 Glypromate 56 huC# DM4 56 bepotastine besilate nasal spray 56 subgroup analyzes 56 thetreatment 56 USpella 56 Phase IIb Trial 56 Pamidronate 56 Arimidex Tamoxifen Alone 56 Therapeutics TCT 56 Early Relapsing Multiple 56 practitioners internists 56 First Patient Enrolled 56 Phase 2b study 56 Oral Insulin Capsule 56 Preclinical Models 56 eritoran 56 confirmatory Phase III 56 thalidomide Thalomid 56 Diabetic Macular Edema 56 lexidronam injection 56 INTERHEART study 56 Phase III confirmatory 56 ST Segment Elevation 56 ASCO GU 56 Zenvia ™ 56 Spiriva Handihaler 56 PROPEL trial 56 PF # [002] 56 landmark ATHENA trial 56 Aryplase 56 Cardiac catheterization 56 randomized multicenter Phase III 56 OVATURE 56 resectable pancreatic cancer 56 invasive candidiasis 56 Venous Thromboembolism 56 COR Analyzer 56 Prostate AdenoCarcinoma Treatment 56 GetGoal Phase III 56 Sanofi aventis EURONEXT SAN 56 UPLYSO 56 BENICAR HCT 56 Cordis Cypher 56 CRMD# 56 Clinical Trial Results 56 Heart Transplant Recipients 56 Accelerated Partial Breast Irradiation 56 mITT population 56 COU AA 56 controlled multicenter Phase 56 Acute Coronary Syndrome 56 Clinical Efficacy 56 icatibant 56 DEB# 56 phase III ACCLAIM 56 TAXUS V 56 glucocorticoid induced osteoporosis 56 Intravascular 56 Autologous Stem Cell Transplantation 56 adult chronic ITP 56 INTEGRILIN R 56 Sorafenib HCC Assessment 56 GP IIb IIIa inhibitors 56 PROactive Study 56 Patients Treated With 56 TOCCATA 56 duplex ultrasonography 56 Matrix Phase 2b 56 Tarceva TM 56 ARCOXIA 56 Phase 2a clinical 56 ISEL 56 Investigational Treatment 56 APEX AMI trial 56 Dr. Fehlings 56 prospectively enrolled 56 PEGINTRON TM 56 randomized controlled clinical trials 56 docetaxel Taxotere R 56 HDL Selective Delipidation 56 Dalbavancin 56 Infarct 56 Multiple Ascending Dose 56 bevirimat Study 56 ORENCIA ® 56 GRAVITAS trial 56 SYNERGY Stent 56 Apixaban 56 Gemzar ® 56 Interagency Registry 56 Phase III ADT 56 recurrent herpes labialis 56 CT Angiography 56 diagnostic angiography 56 Multicenter Randomized 56 sirolimus eluting stents 56 Telmisartan 56 Androxal TM 56 Vascular Wrap 56 Pyridorin 56 Clostridium difficile Infection 56 Anti Bacterial Envelope 56 metaanalysis 56 Dacogen injection 56 REG1 56 Registry NOPR 56 Tryton Side Branch 56 unstable angina pectoris 56 AMEX RGN 56 randomized double 56 blind randomized 56 Cotavance 56 Resolute stent 56 XIENCE TM 56 SYMMETRY trial 56 Multi Ethnic Study 56 VITAL Trial 56 Phase Ia 56 Stent Graft 56 atrial fibrillation ablation 56 Clinical Trial Evaluating 56 Multiethnic Study 56 PLX STROKE targeting 56 Paroxysmal Nocturnal Hemoglobinuria PNH 56 AACR San Antonio 56 label multicenter randomized 56 Chemoradiation 56 TAXUS paclitaxel eluting coronary 56 Microwave Ablation System 56 Double Blind Placebo 56 Resolute DES 56 Ischemic 56 polyarticular 56 ATACAND 56 Phase III randomized controlled 56 PREVAIL 56 reslizumab 56 Spirus Medical 56 AGGRASTAT R tirofiban hydrochloride 56 VNP#M 56 Denufosol 56 AEGR 56 Tolvaptan 55 gadobutrol 55 Quinamed 55 acute peripheral arterial 55 Diabetic Macular Edema DME 55 IMPACT DCM clinical 55 XYOTAX TM 55 descending thoracic 55 #:#-# [031] 55 Acute Coronary Syndromes ACS 55 STICH 55 randomized discontinuation trial 55 vinca alkaloid 55 Warfarin Coumadin 55 Everolimus Eluting Coronary Stent 55 plus DOXIL 55 Liraglutide Effect 55 BENICAR 55 Sapacitabine 55 Mycophenolate Mofetil 55 JAK inhibitor 55 Patients Undergoing 55 nondiabetic patients 55 Oral Fingolimod 55 Achieves Primary Endpoint 55 dalteparin 55 multicenter clinical trials 55 de novo coronary 55 Late Breaker 55 Phase IIb kidney transplant 55 Edwards SAPIEN valve 55 CardioFit 55 REVEAL Registry 55 PDX pralatrexate 55 RIO Diabetes 55 Drug Eluting 55 GISSI 55 OZURDEX 55 REGARDS 55 Fractional Flow Reserve 55 BrachySil TM 55 Vicinium TM 55 Ranolazine 55 Advanced Melanoma 55 Biodesix 55 Laura Mauri 55 Meta Analysis 55 CERVARIX 55 allogeneic hematopoietic stem cell 55 Levacor 55 bioequivalency 55 verteporfin 55 ELACYT 55 CTRC AACR San Antonio 55 #:# -# [003] 55 Acute Stroke 55 Preclinical Study 55 BLP# Liposome Vaccine 55 radiolabeled TM# 55 oral rivaroxaban 55 preclinical efficacy 55 TAXUS Element Paclitaxel Eluting 55 Endeavor Resolute 55 Stent Restenosis 55 STARFlex R 55 IFN alfa 55 Cardiotoxicity 55 OvaRex MAb 55 hypervascular tumors 55 mertansine 55 Severe Asthma 55 Glucosamine Chondroitin Arthritis 55 keloid scarring 55 Anturol TM 55 valve implantation 55 dual endothelin receptor antagonist 55 Edoxaban 55 FDG-PET/CT 55 medically inoperable 55 Kahalalide F 55 EBUS FNA 55 International Verapamil SR 55 PRECISE trial 55 multinational multicenter randomized 55 PROMUS 55 Zilver PTX 55 heFH 55 Endovascular System 55 COMFORT II 55 VICTOR E3 55 MGuard ™ 55 renal artery stenting 55 TASKi2 55 rALLy trial 55 IMiDs ® compound 55 Women Ischemia Syndrome 55 Daxor 55 BERKELEY CA UroToday.com 55 CoreValve System 55 ACCEDE 55 orally inhaled migraine 55 HuMax EGFr 55 #-# Full Text 55 ASPIRE HIGHER 55 relapsing remitting MS RRMS 55 Diabetic Foot Ulcer 55 Phase Ib Clinical Trial 55 Meets Primary Endpoint 55 Risk Stratification 55 Proxinium TM 55 dabigatran etexilate 55 Dr. Adnan Kastrati 55 prospective observational studies 55 Aortic Valve Replacement 55 ID NCT# 55 CLIRS 55 Digestive Diseases Week 55 Hernia Repair 55 Sustained Efficacy 55 Myocet 55 Auxilium Pharma 55 Celebrex celecoxib 55 anti arrhythmic drug 55 symptomatic BPH 55 EASE Trial 55 EOquin TM 55 galiximab 55 Gastric Cancer 55 sunitinib malate 55 ALLHAT 55 CA9 SCAN 55 PNT# 55 patients undergoing CABG 55 Outcome Sciences 55 atrasentan 55 DSMB